Free US stock valuation multiples and PEG ratio analysis to identify reasonably priced growth companies with attractive risk-reward profiles. Our valuation framework helps you find stocks with the right balance of growth and value characteristics for your portfolio. We provide P/E analysis, PEG ratios, and relative valuation metrics for comprehensive valuation coverage. Find value in growth with our comprehensive valuation analysis and multiples tools for growth at a reasonable price strategies.
This neutral financial analysis evaluates Biogen Inc.’s (BIIB) recently announced up to $850 million licensing deal with TJ Biopharma for exclusive Greater China commercial rights and global development rights to felzartamab, an anti-CD38 immunotherapy candidate targeting relapsed/refractory multipl
Biogen Inc. (BIIB) - Acquires Felzartamab Greater China Rights to Challenge Janssen's Darzalex Multiple Myeloma Dominance - EV/EBITDA
BIIB - Stock Analysis
3226 Comments
1670 Likes
1
Marchelo
New Visitor
2 hours ago
Ah, missed out again! 😓
👍 240
Reply
2
Dilara
Active Contributor
5 hours ago
Makes understanding recent market developments much easier.
👍 209
Reply
3
Jovann
Regular Reader
1 day ago
Free US stock growth rate analysis and revenue trajectory projections for identifying fast-growing companies with accelerating business momentum. Our growth research helps you find companies with accelerating momentum that could deliver exceptional returns in the coming quarters. We provide revenue growth analysis, earnings acceleration indicators, and growth scoring for comprehensive coverage. Find growth companies with our comprehensive growth analysis and trajectory projections for growth investing strategies.
👍 40
Reply
4
Brisen
Power User
1 day ago
I feel like I need to find my people here.
👍 90
Reply
5
Wavelene
Influential Reader
2 days ago
Anyone else trying to catch up?
👍 233
Reply
© 2026 Market Analysis. All data is for informational purposes only.